AMJEVITA
These highlights do not include all the information needed to use AMJEVITA™ safely and effectively. See full prescribing information for AMJEVITA. AMJEVITA (adalimumab-atto) injection, for subcutaneous use Initial U.S. Approval: 2016 AMJEVITA (adalimumab-atto) is biosimilar to HUMIRA (adalimumab).
b7178e36-6787-45ab-8fee-be59bc6a4aa4
HUMAN PRESCRIPTION DRUG LABEL
Aug 14, 2023
Amgen USA Inc.
DUNS: 962075045
Products 2
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
adalimumab-atto
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (6)
adalimumab-atto
Product Details
FDA regulatory identification and product classification information